NeuroScientific hails 80% clinical response in Crohn’s stem cell program

NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients improving and no serious adverse events.

Go to News Site